Hjem › Makuladegeneration
Makuladegeneration kliniske forsøg rekrutterer i USA
55 studier for Makuladegeneration rekrutterer deltagere på steder over hele USA.
Byer med flest studier
- Dallas, TX13 studier
- Erie, PA10 studier
- The Woodlands, TX9 studier
- Sacramento, CA8 studier
- Reno, NV8 studier
- Hagerstown, MD8 studier
- Phoenix, AZ7 studier
- Cleveland, OH7 studier
- Houston, TX7 studier
- Salt Lake City, UT7 studier
- Boston, MA7 studier
- Austin, TX7 studier
- Carmel, IN7 studier
- Fort Worth, TX7 studier
- Santa Monica, CA7 studier
- Washington, DC6 studier
- Cincinnati, OH6 studier
- McAllen, TX6 studier
- Philadelphia, PA6 studier
- Portland, OR6 studier
- Mountain View, CA6 studier
- Nashville, TN6 studier
- Columbia, SC6 studier
- Raleigh, NC6 studier
- Naperville, IL6 studier
- Durham, NC5 studier
- Spokane, WA5 studier
- Pensacola, FL5 studier
- Eugene, OR5 studier
- Fort Lauderdale, FL5 studier
- Tampa, FL5 studier
- Lynchburg, VA5 studier
- Orlando, FL5 studier
- Syracuse, NY5 studier
- San Francisco, CA5 studier
- San Antonio, TX5 studier
- Sarasota, FL4 studier
- Ann Arbor, MI4 studier
- Jacksonville, FL4 studier
- Memphis, TN4 studier
Efter delstat
- Arizona11 studier
- Californien20 studier
- Colorado7 studier
- Connecticut6 studier
- Florida14 studier
- Georgia6 studier
- Illinois13 studier
- Indiana7 studier
- Maryland11 studier
- Massachusetts14 studier
- Michigan9 studier
- Minnesota5 studier
- Mississippi5 studier
- Missouri5 studier
- Nevada8 studier
- New Jersey7 studier
- New York10 studier
- North Carolina11 studier
- Ohio11 studier
- Oklahoma3 studier
- Oregon9 studier
- Pennsylvania17 studier
- South Carolina8 studier
- Tennessee7 studier
- Texas24 studier
- Utah9 studier
- Virginia7 studier
- Washington8 studier
- Wisconsin6 studier
Nyligt opdaterede studier
Officiel studietekst (engelsk)
National Eye Institute Biorepository for Retinal Diseases
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alder 2 til 120 · Alle køn · Opdateret 2. okt. 2026 · NCT01496625A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
RekruttererFase 2/3
Alder 50 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT07440225A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
RekruttererFase 2/3
Alder 60 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT06635148A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration
RekruttererFase 1/2
Alder 55 og opefter · Alle køn · Opdateret 23. sep. 2026 · NCT07029945Cell Collection to Study Eye Diseases
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
1 Day – 120 Years · Alle køn · Opdateret 22. sep. 2026 · NCT01432847A Study in Adults With Geographic Atrophy
RekruttererFase 2
Alder 60 og opefter · Alle køn · Opdateret 21. sep. 2026 · NCT07606365A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
RekruttererFase 3
Alder 50 til 85 · Alle køn · Opdateret 18. sep. 2026 · NCT06541704A Study About the Safety of a Single ASP2020 Eye Injection and if it Helps People With Vision Loss From Stargardt-type Eye Conditions
RekruttererFase 1
Alder 6 og opefter · Alle køn · Opdateret 16. sep. 2026 · NCT07734064The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 16. sep. 2026 · NCT06319872A Phase 2 Study of NT-101 Topical in Patients With Wet AMD
RekruttererFase 2
Alder 50 og opefter · Alle køn · Opdateret 16. sep. 2026 · NCT07811726Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
RekruttererFase 2
Alder 55 og opefter · Alle køn · Opdateret 10. sep. 2026 · NCT06659445Noninvasive Imaging Biomarkers of Treatable Macrovascular Disease in Age-related Macular Degeneration.
RekruttererObservationsstudie
Alder 50 til 80 · Alle køn · Opdateret 3. sep. 2026 · NCT07798323A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
RekruttererFase 1
Alder 50 og opefter · Alle køn · Opdateret 3. sep. 2026 · NCT03178149A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)
RekruttererObservationsstudie
Alder 55 og opefter · Alle køn · Opdateret 3. sep. 2026 · NCT07144137Effect of Lutein, Zeaxanthin, and Meso-Zeaxanthin Supplementation on Skin Carotenoid Concentration: A Six-Month, Placebo-Controlled Crossover Study
RekruttererFrivillige med god helbredstilstand velkomne
Alder 18 og opefter · Alle køn · Opdateret 1. sep. 2026 · NCT06965426A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD
RekruttererObservationsstudie
Alder 50 og opefter · Alle køn · Opdateret 1. sep. 2026 · NCT06346600SGLT2 Inhibitors in Geographic Atrophy
RekruttererFase 2
Alder 50 og opefter · Alle køn · Opdateret 26. aug. 2026 · NCT07174687Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration
Rekrutterer
Alder 60 og opefter · Alle køn · Opdateret 26. aug. 2026 · NCT06662162A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults
RekruttererObservationsstudie
Alder 6 og opefter · Alle køn · Opdateret 25. aug. 2026 · NCT074255744D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
RekruttererFase 1/2
Alder 50 og opefter · Alle køn · Opdateret 21. aug. 2026 · NCT05197270A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD
RekruttererFase 2
Alder 55 og opefter · Alle køn · Opdateret 20. aug. 2026 · NCT06659549Phase 1 Study of C.001 in Retinal Degeneration
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 17. aug. 2026 · NCT07594236AMD and Validation Rod-Meditated Dark Adaptation With Everyday Task Performance
RekruttererFrivillige med god helbredstilstand velkomne
Alder 50 til 89 · Alle køn · Opdateret 10. aug. 2026 · NCT06619405A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
RekruttererFase 2/3
Alder 50 og opefter · Alle køn · Opdateret 6. aug. 2026 · NCT07496567Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants
RekruttererFase 1
Alder 50 og opefter · Alle køn · Opdateret 5. aug. 2026 · NCT07230834Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.